Why the study?
Does multimodality therapy improve disease-free survival in patients with angiosarcoma of the breast?
Does multimodality therapy improve disease-free survival in patients with angiosarcoma of the breast?
Multimodality therapy including surgery, radiotherapy, and Adriamycin may offer prolonged disease-free survival in patients with angiosarcoma of the breast.
Answers are grounded in this paper and cite their sources.
May support prolonged remission with multimodality therapy in breast angiosarcoma; hypothesis-generating and requires prospective validation.
Five patients with angiosarcoma of the breast were treated with surgery, radiotherapy and an adjuvant Adriamycin containing regimen. Two patients remain disease-free at 38+ and 20+ months. The median survival of previously reported cases is 22 months with only five patients disease-free at five years. Possible hormonal influences in the etiologic cause of angiosarcoma of the breast are discussed and the importance of early diagnosis and treatment in these relatively young patients is emphasized.
No takes yet. Share an insight, caveat, or question.
Antman et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: